Cutaneous leishmaniasis treatment
- 31 October 2006
- journal article
- review article
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 5 (3) , 150-158
- https://doi.org/10.1016/j.tmaid.2006.09.004
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Les effets indésirables du Glucantime® en intralésionnel dans le traitement de la leishmaniose cutanéeMedecine Et Maladies Infectieuses, 2006
- Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004The Lancet Infectious Diseases, 2005
- Advances in leishmaniasisPublished by Elsevier ,2005
- Amphotéricine B liposomale en première intention dans la leishmaniose viscérale infantile en région Provence–Alpes–Côte-d'Azur–CorseArchives de Pédiatrie, 2005
- Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?International Journal of Antimicrobial Agents, 2005
- Treatment of cutaneous leishmaniasis among travellersJournal of Antimicrobial Chemotherapy, 2004
- Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patientsFundamental & Clinical Pharmacology, 2003
- Leishmaniasis in TurkeyActa Tropica, 2002
- Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st centuryClinics in Dermatology, 1999
- Treatment of cutaneous antimony: intramuscular administration leishmaniasis with versus intralesionalPathogens and Global Health, 1997